SynAct Pharma AB

SYNACT · Nasdaq Stockholm · Healthcare

17.80SEK +3.6%last day

Price as of 2 October 2026

The price over the past year, with dividends: −20.4%

Performance

1 month

+2.1%

1 year

−20.4%

3 years, per year

+0.4%

5 years, per year

−29.3%

Largest fall, 3 years

−96.3%

Below the peak now

−87.5%

Volatility, 1 year

69.9%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

5.6

Dividend yield

0.0%

Return on equity

−61.8%

Net margin

–

Market value

100 m USD

Quality, value and trend

Where SynAct Pharma stands against every Nordic stock today. 100 is best.

Quality65

Profitability and a sound balance sheet over time. Better than 65% of Nordic stocks.

Value3

The price measured against earnings, assets and cash flow. Better than 3% of Nordic stocks.

Trend29

The price development over the past year. Better than 29% of Nordic stocks.

Combined17

Quality, value and trend together. Better than 17% of Nordic stocks.

About SynAct Pharma

SynAct Pharma AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 8 employees.

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis; host targeted treatment for viral infections such as respiratory infections, dengue virus, as well as polymyalgia rheumatica (PMR); and idiopathic membranous nephropathy. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis